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Female and male brains differ. Differences begin early during
development due to a combination of genetic and hormonal
events and continue throughout the lifespan of an individual.
Although researchers from a myriad of disciplines are begin-
ning to appreciate the importance of considering sex differ-
ences in the design and interpretation of their studies, this is
an area that is full of potential pitfalls. A female’s reproductive
status and ovarian cycle have to be taken into account when
studying sex differences in health and disease susceptibility,
in the pharmacological effects of drugs, and in the study of
brain and behavior. To investigate sex differences in brain
and behavior there is a logical series of questions that should
be answered in a comprehensive investigation of any trait.
First, it is important to determine that there is a sex difference
in the trait in intact males and females, taking into consider-
ation the reproductive cycle of the female. Then, one must
consider whether the sex difference is attributable to the ac-
tions of gonadal steroids at the time of testing and/or is sex-
ually differentiated permanently by the action of gonadal
steroids during development. To answer these questions re-
quires knowledge of how to assess and/or manipulate the hor-
monal condition of the subjects in the experiment appropri-
ately. This article describes methods and procedures to assist
scientists new to the field in designing and conducting exper-
iments to investigate sex differences in research involving
both laboratory animals and humans. (Endocrinology 146:
1650–1673, 2005)
WITHIN THE BASIC AND CLINICAL scientific com-munity, there is increasing recognition that differ-
ences between males and females, across the lifespan, affect
an individual’s health, his/her development of disease, signs
and symptoms of pathophysiology, and response to therapy.
Scientists new to the field, however, can be daunted by meth-
odological concerns, which represent a serious barrier to
research. Potential investigators of sex/gender difference
want to be know the answers to the following questions.
What is a good experimental design for studying sex/gender
differences in humans and other animals? What controls do
we need? How do we consider hormones? How do we best
measure or otherwise assess and manipulate hormonal mi-
lieu? How do we incorporate interacting sex/gender factors
in our experimental design and in interpreting our data?
How will studies that include or add assessments of sex/
gender issues affect costs? Although investigators who are
new to the field can find some answers by scouring the
literature or consulting experts who do such research, there
are no published sources currently available that provide
overall and comprehensive guidelines.
This article was conceived from discussions held among
the members of the Isis Fund Network on Sex, Gender, Drugs
and the Brain, sponsored by the Society for Women’s Health
Research. The Society for Women’s Health Research is ded-
icated to building research capacity to study biological dif-
ferences between males and females. Our discussions lead us
to conclude that the difficulty of working with both male and
female animals to scientists not familiar with all of the con-
siderations and pitfalls is a major barrier to advances in the
field. The purpose of this monograph is to offer guidelines
and, in doing so, facilitate the initiation of new research. The
intention is to give investigators interested in pursuing re-
search on sex differences as many resources as possible to
enable development and data interpretation of a well-
designed study. It is important to note, however, that this
monograph should be viewed simply as a guide, not a pre-
scription for the right way to do such work.
The article begins with an overview of mammalian sexual
differentiation and ontogeny of sex differences. Then it an-
swers questions that new investigators might pose with ad-
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ditional references for more details. Because many of the
questions are appropriate for both clinical and basic research,
this manuscript provides guidance for both.
Introduction
Sexual dimorphism in mammals begins early during de-
velopment as a result of a combination of genetic and hor-
monal events and continues throughout the lifespan. Phys-
iological sex differences account for marked differences in
disease incidence, manifestation, prognosis, and treatment
observed between the sexes. Differences in disease suscep-
tibility, time of onset of symptoms, and drug response have
become evident in diseases such as cancer, obesity, coronary
heart disease, and autoimmune and mental health disorders,
among others. In 2001, the Institute of Medicine (IOM) Com-
mittee on Understanding the Biology of Sex and Gender
Differences published its findings in a landmark report, “Ex-
ploring the Biological Contributions to Human Health: Does
Sex Matter?” (1). This report highlights the need to conduct
hypothesis-driven biomedical studies that take into account
sex as a basic human variable. The IOM report validates the
need for research on sex-based differences at the molecular,
cellular, and whole organism levels and at different stages of
the life span. The IOM committee further recommends the
use of animal models that best mimic conditions being
addressed.
Although researchers from a myriad of disciplines are
beginning to appreciate the importance of considering sex
differences in the design and interpretation of their studies,
this is an area that is full of potential pitfalls. A female’s
reproductive status and ovarian cycle have to be taken into
account when studying sex differences in health and disease
susceptibility or in the pharmacological effects of drugs. To
facilitate the consideration of these variables in work in dif-
ferent fields, it is our goal to discuss many of the issues that
are important for proper design of studies on sex differences.
Definition of terms (see also the glossary at the end
of this article)
A sex difference in a trait occurs when normal males and
females of a species differ in that trait. The trait is said to be
sexually dimorphic because it occurs in two forms, one form
typical of males and the other typical of females. Traits may
differ in their mean, variability, temporal progression, or
developmental profile. Sex differences may be transient (re-
versible) or permanent.
Masculine and feminine are used to describe traits that are
typical of males and females of a species, respectively.
Masculinization and feminization refer to any change that
makes an animal more like typical males or females.
Demasculinization and defeminization refer to any change
that makes an animal less like typical males or females.
Masculinization and defeminization are not synonymous
because the differentiation of tissues subserving feminine
functions can be independent of differentiation of tissues
subserving masculine functions (2). For example, some treat-
ments may masculinize, but not defeminize.
Although these definitions are rather general, it should be
noted that in the behavioral neuroendocrine literature, mas-
culinization and feminization typically refer to permanent
(organizational) effects of testosterone and its metabolites,
usually not to the more transient (activational) effects of
hormones in adulthood. The present review emphasizes
work on mammals, but many of the conceptual issues and
experimental designs can be applied to other species, espe-
cially vertebrates.
Conceptual framework: the origins of sex differences
All biological sex differences are initiated by genes en-
coded on the sex chromosomes. All other known inherited
factors (e.g. autosomal genes, mitochondrial genes, and cy-
toplasmic factors derived from the egg) on average are
thought to be inherited equally by males and females. Al-
though two individuals may differ in any of these inherited
factors, the only factors that are consistently inherited in a
sex-specific fashion are those on the sex chromosomes. The
difference between XY and XX cells is potentially attributed
to 1) the presence of Y genes only in male cells, 2) the po-
tentially higher dose of X genes in XX cells than in XY cells;
and 3) the presence of a paternal genomic imprint on the X
chromosome that occurs only in females (see Ref. 3 for fur-
ther discussion).
A critical gene on the mammalian Y chromosome is SRY,
the testis-determining gene. This gene causes the embryonic
undifferentiated gonad to develop into a testis rather than an
ovary (4). This developmental decision is the primary event
determining whether an individual is phenotypically male or
female. The embryonic testes secrete three hormones: tes-
tosterone, Müllerian-inhibiting hormone, and IGF-3. Mülle-
rian-inhibiting hormone causes regression of the Müllerian
ducts, which are otherwise destined to form the oviducts and
upper vagina. IGF-3 is required for descent of the testes.
These hormones act on specific cells throughout the body
and brain and cause them to develop in a masculine (male-
typical) fashion (5, 6). For example, testosterone enters the
brain during early critical periods of development and causes
the formation of neuronal cell groups and synaptic connec-
tions that control functional and behavioral traits that are
more common in males than in females. In short, testosterone
(and depending on the species, its metabolites dihydrotes-
tosterone and/or 17-estradiol) masculinizes the brain per-
manently by acting during early critical periods of neuronal
development (7–10). When testosterone concentrations are
low, as occurs typically in genetic females, the development
of the brain is feminine. Testosterone also acts elsewhere in
the body to cause masculine patterns of development. It acts
on the urogenital primordia to cause formation of a penis
rather than clitoris, and a scrotum rather than vaginal labia.
Thus, the initial commitment of the primitive gonad to a
testicular fate results in widespread hormone-driven mas-
culinization of numerous tissues.
The actions of SRY and testosterone also have an indirect
effect on the environments that a young animal or person will
experience. In human societies, the sex of a baby is usually
judged by the genital morphology at birth, the presence of a
penis or vagina. Once the sex is determined, the baby or
young child is treated differently depending on whether it is
a boy or girl. In rodents, the mother licks the perineal region
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of her sons more than those of her daughters (11–13). These
differences in environment have profound effects on the
development of gender-specific behavioral repertoires. The
sexual differentiation of the body also means that males and
females have different bodily sensations (e.g. those arising
from male vs. female reproductive functions) and thus can be
conditioned differently by those experiences. Although the
effects of SRY and testosterone on formation of the urogenital
system are events that happen prenatally in humans and
other mammals, the effects of hormones on the developing
central nervous system extend into early postnatal life in
many species, including rats and mice.
Long after the fetal and postnatal periods of sexual dif-
ferentiation of the brain and body, the gonads continue to be
a major contributor to sex differences in brain and behavioral
traits. In laboratory rodents, for example, males are exposed
to high concentrations of testosterone, which is secreted by
the testes more or less continuously. In contrast, the major
secretions of the ovary are estrogens (particularly the potent
estrogen, 17-estradiol) and progestins (particularly proges-
terone), which fluctuate in concentration during the estrous
cycle and pregnancy. These circulating gonadal steroid hor-
mones act to influence brain activity differently in males and
females. (Large fluctuations in hormone concentrations oc-
cur in both sexes in seasonally breeding mammals, because
of the period of reproductive quiescence tied to specific en-
vironmental conditions.) Traditionally these activational ef-
fects are transient (they do not last long after steroid con-
centrations decline) and are contrasted with the permanent
organizing or differentiating effects of early gonadal secre-
tions (14, 15).
Virtually all sex differences in brain and behavioral phe-
notypes are attributed to the actions of gonadal steroids, in
combination with environmental events, on the brain and
other target tissues. The genetic sex of brain cells is also
theoretically a source of sexually dimorphic information. For
example, genes encoded on the Y chromosome are expressed
in the brains of males and could have a male-specific effect
if other genes in females do not mimic their role. Moreover,
genes encoded on the X chromosome may be expressed at a
different level in the brains of females and males. In a few
cases, these putative sex-specific, cell-autonomous actions of
sex chromosome genes have been implicated as the cause of
some sex differences in the brain and other tissues in mam-
mals and birds (16). Beyond the roles of gonadal steroids and
genes, behavioral phenotypes in humans may also be influ-
enced by sex differences in experience or cultural factors.
This brief review of the causes of sex differences leads to
a logical series of questions that should be answered in a
comprehensive investigation of the origins of sex differences
in any brain or behavioral trait in mammals.
Designs and Methods for Research on Sex
Differences
The same fundamental questions and experimental design
issues apply across a broad range of content areas that re-
searchers might choose to investigate (see Fig. 1). Theoretical
considerations as well as practical methods for the competent
study of sex differences are discussed in the following sec-
tions. For each question we give examples of studies that
have taken the approach or used the treatments being
discussed.
Question 1: is there a sex difference in the trait?
One might think that to study sex differences, a two-group
design in which one simply measures the trait in a group of
males and a group of females and tests whether the two
groups differ is sufficient. To compare males and females,
however, one must determine the age at which testing will
occur, consider the environments in which they have devel-
oped, the time of day of the testing, the appropriate method
of measurement of the trait, etc. In short, knowledge of the
individual’s biology is important as well as a knowledge of
the environments and testing situations that would be op-
timal for testing for a sex difference. Some sex differences
occur only in certain environments, at specific ages, or at
particular stages of the reproductive cycle. If one finds a
group difference in a trait in males vs. females, one can
conclude that the there is a sex difference in the trait at least
when it is measured under those conditions. For practical
purposes, it is often of interest to determine whether there is
a sex difference in adults of reproductive age. It would be an
error, however, to simply assume the observed sex difference
will generalize to other ages or conditions.
There are occasionally dramatic effects of ovarian steroid
hormones on sexually dimorphic traits, so it may not be
sufficient to measure females at random throughout the re-
productive cycle. In fact, many traits will differ as a function
of day of the female’s reproductive cycle. A better approach
is to compare males with two or more groups of females
FIG. 1. Logical series of experimental questions. The figure illus-
trates an ordered and logical series of questions that can guide the
investigator who wishes to understand the biological origins of sex
differences in a trait. The questions and methods to answer them are
explained in greater detail in the text. If a sex difference is detected
in gonad-intact animals, the most likely reasons are sex differences
in the effects of gonadal hormones around the time of testing (Q2), or
permanent differences caused by the action of gonadal hormones
during fetal or neonatal life (Q3). If gonadectomized males and fe-
males are tested after being given equivalent hormone treatments
and there is a sex difference, then it is possible that there is both a
role for sex hormones around the time of testing and a permanent
differentiating effect of gonadal steroids on the trait, in which case
even if the answer to Q2 is yes, it is still appropriate to ask Q3. Q,
question.
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where the stage of the ovarian cycle is known. A three-group
design in rats, for example, could compare males with fe-
males on two specific days of the estrous cycle. A five-group
design would compare males with females on each of the
four days of the rat estrous cycle (e.g. Ref. 17). The results of
the study would show whether males and females differ on
the trait and, if so, on which estrous cycle days (see Question
5). This experimental design has the potential to indicate
whether actions of gonadal steroids at the time of testing
could influence the dependent measure. Because other vari-
ables co-vary with the ovarian cycle, any estrous or men-
strual cycle effects that are found need to be verified in
follow-up studies in which hormone concentrations are ex-
perimentally manipulated to determine the role that the spe-
cific hormones play in affecting the dependent variable (see
Questions 2 and 6).
If a trait varies with the ovarian cycle, it is by definition a
sexually dimorphic trait because males will not show the
same cyclical variation (because they don’t have an ovarian
cycle). With a simple two-group design discussed in the last
paragraph, if females differ from males on some, but not all,
days of the estrous or menstrual cycle when females are
selected randomly, they may not be randomly distributed
across the cycle, and a sex difference could be missed. This
is particularly true if the sample size is small or if all females
are measured on the same day, because female rodents, hu-
mans, and other mammals that spend a lot of time together
may synchronize their cycles (18–20). Even if females used
in an experiment are at different stages of the ovarian cycle,
a sex difference could be missed because of the variability
among the animals in the group.
Measuring a trait in gonadally intact males and females is
important because it gives information on the trait measured
under natural conditions, with all endocrine feedback sys-
tems operating and all natural gonadal secretions operating.
The presence of a sex difference, however, does not tell you
which hormones, if any, are important for their effects on the
trait being measured.
Question 2: is the sex difference attributable to the actions
of gonadal steroids at the time of testing?
The following sections discuss methods used, first in lab-
oratory animals (primarily rats and mice) and then in
humans.
Laboratory animals. Once a sex difference is detected, the next
step is to determine whether gonadal secretions cause or
affect the difference by acting just before or during the time
of testing (see Fig. 1, Q2). In studies with laboratory animals,
the classical method to answer this question has two stages,
endocrine ablation and hormone replacement therapy. First,
the gonads of males and females are removed (controls are
operated on and the gonads are externalized and then re-
placed, a procedure called sham gonadectomy), and the trait
is measured. Depending on the trait of interest, it may be
necessary to wait days or weeks for the effects of gonadal
secretions to wear off. Indeed, the time after gonadectomy
can be varied to determine how fast the effects subside, if this
is relevant. If gonadectomy changes the trait in one sex, then
one concludes that the gonads are important for the trait in
that sex (e.g. Ref.21). One cannot conclude strictly at this stage
that gonadal secretions influence the trait because other fac-
tors (e.g. neural afferents from the gonad) are also manipu-
lated by gonadectomy. If gonadectomy abolishes the sex
difference, then by Occam’s razor there is no need to invoke
any other factors (e.g. permanent masculinizing effects of
testosterone during fetal life) as the source of the sex differ-
ence. If gonadectomy abolishes the sexual dimorphism, it is
still possible that two sex-specific factors, such as hormonal
and genetic factors, operate in a sex-specific fashion to coun-
teract each other, reducing rather than producing sex dif-
ferences in phenotype (22).
If gonadectomy in nonhuman animals changes the trait in
one sex, the second step is to administer gonadal steroids to
gonadectomized animals (controls receive placebo treat-
ment) to determine whether the gonadal steroids cause the
trait to return to its natural state (i.e. the state typical of
gonadally intact animals). This experiment can be performed
in a three-group design: gonadectomized animals given go-
nadal steroid, gonadectomized given placebo, and intact con-
trols. If testosterone treatment in castrated males returns
their phenotype to that of an intact male after a given time
period, the result strongly supports the idea that testosterone
from the testes influences the trait, directly or indirectly (e.g.
Ref. 23). To reach this conclusion it is important that the
concentrations of gonadal steroid be within the physiological
range; otherwise, pharmacological effects of the hormone can
be observed. It should also be noted that the effect of a
hormone treatment can vary with the time after treatment,
because steroid hormones can have both rapid effects as well
as effects that are not seen for days or months. So, choosing
appropriate time points is another thing to think about when
designing the experimental protocol. Another important de-
cision is which gonadal hormones to replace. Depending on
the specific parameters of the experiment, one might wish to
replace the male’s hormones (e.g. testosterone) or the fe-
male’s (e.g. estradiol or progesterone alone or in combina-
tion) (see Question 6).
There are numerous variations on the classic two-step
endocrine experiment. Various drugs are available to block
specific gonadal steroid receptors or the synthesis of steroids
to test the influence of steroid hormones on the trait. Exam-
ples are flutamide, a well-established and effective androgen
receptor blocker (e.g. Ref. 24); tamoxifen, an estrogen receptor
antagonist (e.g. Ref. 25), and RU486, an effective anti-pro-
gestin (e.g. Ref. 26, 27). Fadrozole is an effective inhibitor of
aromatase, the enzyme catalyzing 17-estradiol synthesis
from testosterone (e.g. Ref. 28). Discussion of the huge variety
of steroid hormone agonists and antagonists is beyond the
scope of this paper. It should be noted, however, that use of
these drugs requires some research on the specific applica-
tion before beginning; we have given examples of studies
that have used these agents as a guide. For example, tamox-
ifen is an estrogen receptor antagonist in some systems
(breast and uterus) and an agonist in others (bone), and
RU-486 is active at glucocorticoid receptors as well as at
progestin receptors.
Since the early 1990s, mice have been generated that have
a null mutation (knockout) of specific steroid receptors.
When these mice are compared with control mice of the same
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genetic strain, the influence of a specific steroid receptor can
be measured (e.g. the Tfm mouse that is lacking androgen
receptors and so appears feminine even if the animal has
testes). Knockout mice have allowed the identification, for
example, of previously undetected estrogen receptor-depen-
dent effects on specific traits (e.g. Ref. 29). The knockout mice,
however, do not represent animals in whom all effects of a
specific hormone have been eliminated, because other ste-
roid receptors are often functional in these animals, and
nearly all of the gonadal steroids also act via mechanisms
other than those mediated by their classic receptors. More-
over, when comparing knockout with wild-type mice, the
differences are attributable to the loss of hormone action in
adulthood and/or throughout development, because recep-
tors are absent throughout life. With the advent of condi-
tional knockout mice, in which a receptor can be inactivated
at specific life stages and/or in selected tissues, it should
become possible to specify more clearly the site of action of
the hormone and the life stage at which the trait is influenced
by the hormone acting through specific receptors.
Humans. In humans, one can reduce the variability that stems
from fluctuating hormone concentrations associated with the
menstrual cycle by measuring ovarian steroids at the time of
study and classifying women into groups accordingly (e.g.
(30). Classifying women by stage of the menstrual cycle
defined on the basis of timing or indirect criteria such as
changes in basal body temperature is a less desirable alter-
native, because there are large interindividual differences in
the hormone concentrations attained at each stage. In addi-
tion, self-reports of menstrual cycle stage are notoriously
unreliable. Because the menstrual cycle is only a rough index
of the hormonal profile, it is therefore better methodology to
directly measure ovarian hormones, unless for theoretical
reasons the menstrual cycle itself is of interest (e.g. when
studying the timing of mood changes linked to the cycle) or
when there is a need to prospectively estimate the timing of
future endocrine events.
Women using hormonal contraceptives must be consid-
ered separately, because the contraceptives greatly alter the
endocrine environment in ways that depend on the specific
contraceptive formulation. Studying females in different en-
docrine states or choosing one endocrine state and compar-
ing it with males matched on specific criteria (e.g. age,
education, socioeconomic status, race, etc.) will aid in deter-
mining factors that contribute to variability between women
and within a woman as well as between women and men (see
Questions 7–9).
As in females, hormone concentrations differ systemati-
cally in males as a result of puberty, adolescence, adulthood,
and aging. In men, total testosterone concentrations in serum
drop by approximately 35% and bioavailable testosterone by
50% between ages 30 and 80 (31). There are also circadian and
seasonal variations in testosterone concentrations [this is true
in many species including humans where testosterone is
highest in the early morning and in autumn (32, 33)]. These
biological rhythms need to be taken into account in designing
studies, because the actions of testosterone at the time of
testing might influence the sex differences observed. For
example, it may be necessary to control the time of day at
which measurements are taken or to use stratified sampling
techniques.
In humans, trying to determine the cause of a sex differ-
ence is much more difficult. The gonads cannot be removed
for experimental purposes. Therefore, we must rely on other
methods. These might involve observing the effects of sur-
gical removal of the gonads [e.g. surgical menopause (34),
suppression of gonadal secretions as in men being treated
with antiandrogens for prostate cancer (35), or the effects of
replacement hormones, e.g. hormone replacement therapy
(HRT) in postmenopausal women (36, 37)]. One issue is that
such clinical manipulations are typically carried out in older
persons. Whether aging is accompanied by any changes in
receptors that might affect hormone responsivity is not
known. Although still a valuable strategy, the applicability
of the findings to pubertal girls and young women of re-
productive age is unknown. Another issue is that pure hor-
monal preparations (i.e. those that contain a single hormone
or that are the same as the hormone produced by the body)
are not always used. Exposure to a mixture of estrogens, for
example, is common in HRT. We will further discuss the
methods used in human studies below (see Question 8).
Question 3: is the trait sexually differentiated permanently
by the action of gonadal steroids during pre- and/or
postnatal periods of development?
Laboratory animals. If gonadectomy around the time of testing
(e.g. in adulthood) does not eliminate the sex difference in the
trait, one then suspects that testosterone (or its metabolites
17-estradiol or dihydrotestosterone) might have acted dur-
ing early stages of development to cause permanent sex
differences in development of the tissues mediating the trait
(see Fig. 1, Q3). Another outcome suggesting this hypothesis
is if gonadectomized males and females treated identically
with gonadal steroid(s) show differences in the trait. The
latter situation holds, for example, when the trait occurs only
in the presence of gonadal steroids in one sex. For example,
female sexual behavior in guinea pigs is abolished by ovari-
ectomy but is reinstated in females much more than males
when both are given 17-estradiol followed by progesterone
(38). In sum, permanent sex differences are suspected when-
ever males and females show a difference in a trait under
conditions of equivalent concentrations of circulating go-
nadal steroids. So, if an investigator is following the sequence
of experiments depicted in Fig. 1, there are instances when
there will be a role for hormones at the time of testing (Q2),
and one proceeds to Q3 to investigate whether there are
permanent differentiating effects of gonadal steroids, be-
cause equivalent hormone treatments produced different ef-
fects in males and females.
Two general approaches are used to test the role of tes-
tosterone in sexual differentiation: increase testosterone ex-
posure in females or reduce it in males. The first approach
involves administering physiological doses of testosterone to
females during fetal and/or early postnatal life (controls
receive placebo) and measuring the trait later in life, usually
in adulthood, to determine whether the female is more mas-
culine by virtue of the testosterone treatment (e.g. Ref. 39).
Often it is appropriate to include a placebo-treated male
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control group for comparison. If testosterone treatment
causes females to become more like males, it is possible to
conclude that females can respond to testosterone and that
testosterone can cause masculinization of females. To deter-
mine whether testosterone normally masculinizes the trait in
genetically male animals, the classic endocrine experiment is
performed (endocrine gland removal followed by hormone
replacement) by manipulating exposure to testosterone be-
fore and/or just after birth. A typical approach to reduce the
action of testosterone in prenatal males is to administer an
androgen receptor blocker to the pregnant mother (24). These
drugs pass through the placenta to the fetus. Because many
of the masculinizing actions of testosterone in rodents re-
quire conversion of the testosterone to 17-estradiol in the
brain, estrogen antagonists or aromatase inhibitors are also
given to block normal masculinization of traits in males.
Controls receive placebo. After birth, the hormones are ma-
nipulated by removal of the testes (controls are sham gon-
adectomized). In rats, from gestational d 18 through the first
10 d of postnatal life encompass the critical periods where
several aspects of brain masculinization and defeminization
can occur (9, 10). The trait of interest is often measured some
weeks or months later, under conditions appropriate to the
trait.
If blocking or removing testicular secretions during fetal
or postnatal periods prevents the development of a mascu-
line trait in males, and testosterone (or 17-estradiol) treat-
ment prevents this demasculinization of males and causes
masculinization of females, then the trait is sexually differ-
entiated by the actions of testosterone during the early de-
velopmental period tested. The effects of testosterone are
typically permanent. They can be measured many months
after the endocrine manipulation, long after the steroid hor-
mone itself is no longer present (9, 10).
Often administering testosterone to females causes incom-
plete masculinization, in that the trait in testosterone- or
17-estradiol-treated females is intermediate to that of nor-
mal males and females. The explanation for the incomplete
masculinization of females usually is that the testosterone
treatment does not fully mimic the normal patterns of con-
centrations or timing of hormone exposure found in males.
For example, testosterone treatment during the perinatal pe-
riod does not produce complete masculinization of the phal-
lus in female rodents (7, 10). Similarly, if antisteroids and/or
postnatal castration do not completely prevent masculine
development in males, the investigator might conclude that
the reduction in testicular secretions does not fully mimic the
endocrine state of the developing female. In each case, the
failure to fully cause or prevent masculine development is
not necessarily taken as strong evidence for the importance
of other factors (other hormones or nonhormonal factors) to
cause the sex difference.
Experiments in which the serum concentrations of gonadal
steroids are manipulated allow strong conclusions about the
effects of gonadal steroids during specific developmental
periods but do not necessarily answer the question of
whether the sex difference is entirely explained by gonadal
secretions. In cases in which treatment of females with phys-
iological concentrations of testosterone cause complete sex
reversal (e.g. Ref. 40), there is no need to invoke other possible
causes of the sex difference (41).
In general, experiments such as these show strong effects
of testosterone or in some species its metabolite 17-estra-
diol, which act on the brain to cause masculine patterns of
development. A role for ovarian secretions in bringing about
feminine development of the brain has also been suggested,
but the effects of ovarian secretions appear to be more subtle,
perhaps more limited, and to act in a different time frame
during development (42). The same experimental ap-
proaches described for testosterone above are appropriate
for manipulating the concentrations of ovarian hormones
during various phases of development to determine their
importance in causing sex differences.
Humans. The classic experimental approach involving go-
nadectomy and manipulation of hormones cannot be applied
in human studies. However, sexual differentiation of the
human nervous system and other tissues under the influence
of testosterone might well occur. One approach used in hu-
mans is to study the behavior and physiology of females who
were exposed to high concentrations of androgens prenatally
as a result of endogenous overproduction of androgens by
the adrenal glands. This occurs in genetic females with the
classic form of 21-hydroxylase deficiency, or congenital ad-
renal hyperplasia (CAH). In this condition, excess androgens
are produced in utero, but once cortisone replacement ther-
apy is initiated, usually in the first few weeks after birth,
androgen concentrations become normalized. Therefore, fe-
males with CAH are exposed to high concentrations of an-
drogens during prenatal but not postnatal development. Ac-
cordingly, this is the best available model in humans for
studying the effects of prenatal androgens on sexual differ-
entiation. Psychosexual development and gender role be-
haviors have been the focus of most studies (43, 44), but the
effects of CAH on patterns of gonadotropin secretion, men-
strual cyclicity, and other features of female reproductive
physiology could also be studied.
Although such individuals are rare, it is also possible to
study genetic males who have androgen insensitivity syn-
drome for insights into the role of androgens in sexual dif-
ferentiation of the nervous system. As in other species, the
syndrome is caused by absence or malformation of the an-
drogen receptor, resulting in an inability of the tissues to
respond to androgens. The insensitivity may be partial or
complete. In practice, the study of males with androgen
insensitivity syndrome is complicated by the fact that they
are raised as females and typically take estrogen supple-
mentation (10).
Question 4: do sex chromosome genes act in a cell-
autonomous fashion to cause the sex difference?
In some cases a sex difference may appear not to be ex-
plained by the activational effects of gonadal secretions dur-
ing the time of testing (e.g. adulthood) or by organizational
effects during pre- and postnatal development. If manipu-
lations of sex steroid hormones around the time of testing,
and during fetal and neonatal life, all fail to sex-reverse the
trait, then other factors become more interesting. Several
explanations are possible. One is that gonadal steroids are
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responsible for the sex difference, but they act at a develop-
mental stage that has not yet been tested. In some cases, for
example, steroids acting during puberty may have persistent
effects on traits measured later in life (45, 46). So far, little is
known about the potential for pubertal effects in humans. Of
course, the lack of effect of a hormonal manipulation in
animal studies does not prove that hormones are not in-
volved, because the experiments may have failed to manip-
ulate the hormones effectively (e.g. dose too high or too low,
wrong metabolite used, insensitive measurement of the de-
pendent variable, etc.).
Laboratory animals. Another potential explanation is that
genes encoded on the sex chromosomes (X-linked or
Y-linked genes) act within cells to sexually differentiate XX
and XY cells (Fig. 1, Q4). In this article, this kind of effect is
defined as a sex chromosome effect. This mode of sexual
differentiation is well established in many tissues in inver-
tebrates such as Drosophila melanogaster and Caenorhabditis
elegans (47) and in the mammalian gonad (48). Specific X and
Y genes are implicated in each of these cases. In a few cases,
this mechanism also operates in nongonadal tissues in mam-
mals (49–53). In all of these mammalian cases in which a sex
chromosome effect is inferred, the sex difference can be de-
tected before differentiation of the gonads. Hence gonadal
secretions (e.g. testosterone, Müllerian-inhibiting factor, IGF-
3), which are first secreted after the gonads differentiate,
cannot be responsible for the initial stages of sexual differ-
entiation of the tissue, and a cell-autonomous sex chromo-
some effect is implicated. In each mammalian case, however,
the specific X- or Y-linked genes responsible have yet to be
identified.
To test for a sex chromosome effect to explain sex differ-
ences in a trait that develops after gonadal differentiation,
when hormones cannot easily be dismissed as a contributing
factor, the basic approach would be to manipulate the dose
of X and/or Y genes (or allelic differences in those genes)
while keeping the concentrations of sex hormones as con-
stant as possible. For example, one could detect a sex chro-
mosome effect by finding a sex difference in a trait in XX vs.
XY animals if the gonadal secretions were either entirely
absent throughout life or were held scrupulously constant. In
practice, this has been achieved rarely if at all. Manipulation
of gene expression in an intact mammal is currently eco-
nomical and routinely feasible only in mice and is much more
difficult than manipulation of hormone concentrations. Here
we describe one experimental approach pioneered by Bur-
goyne, Lovell-Badge, and colleagues (49, 54, 55).
A strain of mouse exists in which Sry, the testis-determin-
ing gene, is deleted on the Y chromosome. This Y chromo-
some therefore does not induce testis development. Instead,
XY animals have ovaries and are called females (male and
female here are defined by gonadal phenotype). Some mice
carry an Sry transgene inserted into an autosome making the
mouse XYSry. Phenotypically, the animal is male (with
testes) and breeds normally. When XYSry males are mated
to XY females, four types of progeny result: XYSry males,
XXSry males, XY females, and XX females. These are called
the four core genotypes. If one measures traits in these four
genotypes, the comparison is 2  2 (the factors are gonadal
sex and sex chromosome complement). One can discover
phenotypes that are influenced by hormonal secretions of the
gonads by comparing females and males (either XX females
vs. XXSry males, or XY females vs. XYSry males). These
two comparisons keep the genetic sex of cells constant but
vary the sexual phenotype of the gonads (ovaries vs. testes).
The other comparison keeps the sexual phenotype of the
gonads constant (almost constant, see caveat below) while
varying the genetic sex of cells throughout the body: XY
females vs. XX females; XYSry males vs. XXSry males (56).
For example, if one measures the size of brain nucleus A
in the four core genotypes and finds that A is larger in male
groups than in female groups (XYSry  XY and/or XX-
Sry  XX), the difference is attributable to the action of Sry
(41). The most likely sites of action of Sry to cause a difference
in region A are the gonads because of the well-known role
of gonadal steroids in causing sex differences in the brain and
other somatic tissues. As a shortcut, these comparisons are
said to test for a role of gonadal hormones. However, this
experiment does not rule out an effect of Sry elsewhere in the
body, for example in the brain itself. (Logically, such an effect
is possible, although presently we know of no such actions
of Sry outside the gonad.) On the other hand, if one finds that
region A is (for example) larger in XY mice than XX mice
within sex (XYSry  XXSry and/or XY  XX), then the
conclusion is that the complement of sex chromosomes of
cells causes the group differences. For a more specific ex-
ample of this type of cell autonomous sexual differentiation
of the brain, see Ref. 41. This result does not indicate which
genes are responsible or where they act. They might act, for
example, inside or outside of the brain. The result does not
prove that the sex chromosome effect is nonhormonal be-
cause some hormonal mechanisms could conceivably be in-
volved. Hypothetically, if the adrenals of XY females se-
creted more androgen than those of XX females, the sex
chromosome effect could be mediated by androgens. In the
long run, the mechanisms of action caused by sex chromo-
somes can be elucidated by identifying the genes responsible
and studying their cellular site and mechanisms of action.
Finally, although the two male groups will differ strikingly
from the two female groups in their gonadal secretions, the
two male groups (or two female groups) may differ more
subtly from each other in the concentrations of hormones
secreted by the gonads. Despite this possibility, the two male
groups have been found not to be different from each other,
and the two female groups are not different from each other,
as assessed by measuring several brain regions and behav-
iors that are sensitive to threshold concentrations of gonadal
hormones (41, 57). Therefore, the within-sex differences in
gonadal secretions are likely to be minor.
This example illustrates that the genetic sex of cells (XX vs.
XY) can now be manipulated independently of the sexual
phenotype of the gonads, to begin to dissociate the effects of
sex chromosome genes and gonadal steroids. These studies
are currently feasible only in mice, but we can expect im-
provements in molecular genetics to allow similar experi-
ments in other species. Other mouse models also exist, for
example knockouts of genes such as steroid factor 1, which
are required for gonadal development (58). These models
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allow measurement of responses in mice that lack gonads
entirely.
Research Issues in the Study of Hormone-Behavior
Relations in Adults
This section includes more specific questions and issues
that investigators face when studying hormone-behavior re-
lations within the context of sex differences research.
Question 5: how is the stage of the estrous cycle determined
for the female rat?
Ovarian cyclicity has profound effects on most, if not all, of
the nervous system. In rats, as well as other species, these effects
produce transient changes in behavior. For example, reproduc-
tive behavior, food intake, fluid intake, and locomotor activity
vary markedly with stage of the estrous cycle in female rats
(59–61). The study of estrous cycle effects represents an op-
portunity to study neuronal plasticity and its physiological and
behavioral consequences, yet many investigators remain wary
because published protocols for assessing estrous stage seem
inconsistent and unclear. This issue is addressed by describing
two of the main strategies used for assigning the rat’s estrous
stage in relation to a light-dark cycle. Behavioral endocrinolo-
gists frequently use a 14-h light, 10-h dark cycle or a 12-h light,
12-h dark cycle (see below).
The female rat is a spontaneously ovulating polyestrous
mammal. Ovulation occurs at 4- or 5-d intervals throughout
the reproductive life of the rat, except during pregnancy,
pseudopregnancy, and lactation (60–62). 17-Estradiol and
progesterone are the hormones produced in the largest quan-
tity by the ovaries. During the estrous cycle, 17-estradiol
and progesterone act on the brain to stimulate the hormonal
events that result in ovulation and sexual behaviors (63).
These hormones also act on peripheral receptors and glands
to induce the production of pheromones by the female rat.
Therefore, these hormones will produce qualitative changes
in the value of a female as a stimulus in addition to changing
her behavior. For example, 17-estradiol enhances whereas
progesterone decreases attractiveness of the female rat to a
male rat because of changes in the female’s pheromone pro-
duction (64). For sexual behavior, 17-estradiol primes the
brain for progesterone by inducing the production of pro-
gesterone receptors, and then progesterone activates sexual
receptivity (63).
As mentioned above, female rats have only a 4- or 5-d
estrous cycle (Fig. 2B). This is one of the most rapid ovarian
cycles among mammals, and it is made possible by truncat-
ing the cycle after ovulation. In other female mammals, ovu-
lation is followed by a luteal phase, which is maintained by
hormones produced by the corpus luteum (a transient en-
docrine gland comprising the residual components of the
follicle that remain after ovulation) (63). In rats, the corpus
luteum becomes functional only when the female engages in
sexual behaviors that activate a progestational reflex that
prolongs the secretion of progesterone from the corpus lu-
teum. This reflex induces the release of prolactin from the
anterior pituitary. Prolactin in turn stimulates the corpus
luteum, which in turn secretes progesterone to prepare the
uterus for implantation, and this increases the probability
that pregnancy will occur. Stimulation of the vaginocervical
area by the male rat or the experimenter can induce the
progestational reflex, resulting in a period of corpus luteum
activity that lasts 12–14 d. This condition is known as pseu-
dopregnancy (60, 65).
The estrous cycle. When the aim of an experiment is to de-
termine whether an outcome measure varies with the stage
of the estrous cycle it is important to determine whether
animals are cycling normally. Thus, it is prudent to establish
that at least two complete cycles have occurred before ini-
tiating testing.
Follicular phase. The ovarian cycle begins with the devel-
opment of follicles from oocytes in the ovary. Low concen-
trations of FSH from the pituitary stimulate follicular devel-
opment. There is also increased steroidogenesis at this phase
caused by stimulation by LH. 17-Estradiol secretion in-
creases gradually during this phase. In the rat, this stage is
2 d long. The first day is called diestrus 1 or metestrus, and
the second day is diestrus 2 or just diestrus (Fig. 2B) (63).
FIG. 2. Patterns of estradiol, progesterone, and
LH inhuman (A) and rat (B) during the reproduc-
tive cycle. Time unit of the x-axis in A is days; in
B, it is hours. Dark bars in B indicate dark period
of the day/night cycle. Note that during the fol-
licular phase in humans and its analog in rats
(diestrus), 17-estradiol rises but progesterone
secretion remains low. After the LH surge, pro-
gesterone is elevated in both rat and man. In
humans, the corpus luteum also secretes some
17-estradiol, whereas in rats during the brief
luteal phase, 17-estradiol concentrations de-
cline. [Panel A is adapted with permission from
Fig. 4 in I. Thorneycroft et al.: Am J Obstet Gy-
necol 111:947, 1971 (128). Panel B is adapted with
permission from Fig. 1 in M. S. Smith et al.: En-
docrinology 96:219, 1975 (201). © The Endocrine
Society.]
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Periovulatory period. The time just before and after ovula-
tion is dynamic. 17-Estradiol increases dramatically, acting
on the brain to trigger GnRH release, which induces a surge
of LH from the pituitary that induces ovulation. Progester-
one rises a few hours before ovulation and contributes to this
process. In the rat, this phase is called proestrus (63). Max-
imum 17-estradiol release from the ovary starts 18 h before
ovulation with serum 17-estradiol reaching a peak of 50–
150 pg/ml around 6–12 h before ovulation (60, 65). A sig-
nificant increase in progesterone occurs 4–6 h after the 17-
estradiol surge, during the afternoon of proestrus. The serum
concentration of progesterone at the proestrus peak is ap-
proximately 25–50 ng/ml (60, 65). Once LH and progester-
one are released into the circulation, ovulation occurs 10–12
h later (Fig. 2B).
Estrous phase. Estrus is the period of sexual receptivity and
the actual day of ovulation. Sexual receptivity onset occurs
shortly after the onset of the dark phase of the light-dark
cycle and precedes ovulation by a few hours in most animals
(Fig. 3). Ovulation, induced by the LH surge on proestrus,
occurs 10–13 h after the surge (66), and sexual receptivity
persists for 12–20 h (depending on whether the female mates
or not). Note that behavioral receptivity occurs 36–48 h after
the initial increase in 17-estradiol and 4–6 h after proges-
terone. Baseline serum concentrations of 17-estradiol at
vaginal estrus or behavioral estrus are approximately 3–12
pg/ml (60, 65).
Further details of the stages of the estrous cycle and the
endocrine changes that accompany them can be found in Ref.
67 for the rat, hamster, guinea pig, sheep, dog, and rhesus
monkey.
Nomenclature. Clearly, the estrous cycle is a dynamic pro-
cess with changes happening rapidly, particularly during
proestrus and estrus. This can lead to some confusion and
misunderstanding about findings if the dynamic nature of
the process is not taken into consideration. For example, the
hormonal profile during the morning of proestrus is very
different from on the afternoon of proestrus (60). Further-
more, confusion can occur because of different nomencla-
tures that can be used to determine when a day begins and
ends. Behavioral neuroendocrinologists, for example, fre-
quently define a day of the cycle as beginning with the time
that lights go off in the animal colony so that the entire active
period of the animal’s subjective day falls on one day of the
estrous cycle (see Fig. 3). Other scientists may define a day
as beginning at midnight to be consistent with the scientist’s
subjective day. Given the dynamic nature of the cycle, it
doesn’t really matter which nomenclature is used as long as
FIG. 3. Stage assignment across the rodent’s 4-d estrous cycle in relation to a 12-h light, 12-h dark cycle and samples of vaginal cytology. Shaded
bars located in the upper portion of the figure denote successive 12-h dark periods. Vertical arrows depict the time (early- to mid-light phase)
when vaginal cytology is typically sampled. The gray star denotes the time of ovulation (4–6 h into the dark phase). Representative photomi-
crographs and a brief summary of the types of cells that are predominant during each cycle stage are depicted in the lower portion of the figure.
Examination of vaginal cytology reveals that stages of the estrous cycle range from 8–54 h. By convention, however, scientists refer to stages
of the estrous cycle in relation to our circadian day. A, Traditional stage assignment. Each successive 24-h interval from mid-dark period to
mid-dark period is named for one stage, consistent with the scientist’s subjective day (60, 65). B, Behavioral stage assignment. This strategy
considers the rodent’s behavioral traits that are expressed predominantly during the four successive dark periods. For example, changes in
sexual receptivity, food intake, and locomotor activity occur primarily during the dark period when rodents ovulate (59). Using the traditional
strategy for assigning estrous cycle stage, this period of altered behavioral expression coincides with the end of proestrus and the start of estrus.
The ambiguity created by these behavioral changes spanning two estrous cycle stages has created confusion in the literature. To avoid this
problem, we propose that the 12-h dark period, coincident with ovulation, be referred to as behavioral estrus. To ensure comparison between
studies we also propose that scientists explicitly state assignment of estrous stage in relation to the light-dark cycle as well as the endocrine
events occurring during the time of experimental investigation.
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it is defined and results are interpreted relative to the en-
docrine events happening at the time of the experimental
manipulations.
Determining estrous cycle phase by vaginal lavage. For research
purposes, it is generally preferable to measure hormone con-
centrations in the serum directly if inferences are to be made
about hormone concentrations. However, hormonal changes
associated with the ovarian cycle result in cellular changes in
vaginal cytology. For some research purposes (e.g. verifying
whether an experimental treatment has disrupted the estrous
cycle) it may be sufficient to monitor changes in hormones
indirectly by monitoring changes in vaginal epithelial cells.
Most investigators assign estrous stage using the relatively
noninvasive technique of examining vaginal cytology at 24-h
intervals. Using this technique, it has been determined that
the estrous cycle consists of four stages named diestrus 1
(D1, sometimes referred to as metestrus), diestrus 2 (D2),
proestrus (P), and estrus (E). Each of these stages has varying
lengths (D1, 6–8 h; D2, 55–57 h; P, 12–14 h; and E,
25–27 h), and the specific changes depend on the species
and the light-dark schedule. If samples are obtained at 24-h
intervals, not all of these stages may be sequentially visible
in a set of smears from an individual rat, because some stages
are less than 24 h (60). Note, also, that even though the
nomenclature is the same, these terms do not refer to the
same 24-h periods identified in Fig. 3 and in the paragraphs
above. For example, the vaginal cytology characteristic of
proestrus lasts 12–14 h, not the 24 h associated with the day
of proestrus as identified above. Finally, the vaginal cytology
does not immediately reflect changes in hormonal secretion,
because there is a delay between hormonal secretion and the
morphological changes in the vaginal target cells.
As illustrated in Fig. 4, vaginal lavage is usually done
using an eyedropper and 0.9% saline. The tip of the eye-
dropper is filled with a small amount (one or two drops) of
saline and then inserted into the vagina of the female rat (Fig.
FIG. 4. How to obtain vaginal cells for cytology.
Depicted are two methods commonly used to per-
form vaginal lavage. The photographs shown here
are single images taken from videos of the full
procedure. A–D, Ventral approach in which the
rat is first taken from the cage with the left hand,
held against the chest briefly (A), and then turned
ventral side up (B). Using the right hand, a blunt-
tipped eyedropper is used to insert and quickly
withdraw approximately 0.5 ml (maximum) of sa-
line into the vaginal canal (C). The drop is then
placed on a slide (D) so that vaginal epithelial cells
that have sloughed off into the drop can be viewed
later under a microscope. E–H, Dorsal approach.
In this case, the rat is removed from the cage and
placed on a table. Using the left hand, the rat is
then grasped by the base of the tail (E), which is
then lifted to expose the rat’s vaginal opening (F).
A cotton-tip applicator (moistened with distilled
water or saline) is then inserted into the vaginal
canal (F and G) and twisted rapidly and gently to
accumulate epithelial cells. The cells on the ap-
plicator are transferred onto a slide by pressing
the cotton tip onto the slide and vigorously rolling
the tip to its full circumference (H).
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4, A–D). The fluid is expelled into the vagina and then col-
lected two to three times, or until the saline becomes opaque,
and then the fluid is placed onto a microscope slide. The
eyedropper is thoroughly rinsed with distilled water, and the
next rat is sampled. The resulting sample is examined under
a light microscope (40–100 magnification), while still wet.
Alternatively, a cotton swab, moistened with 0.9% saline,
may be inserted into the vaginal canal and then rapidly
withdrawn (Fig. 4, E–F). The resulting vaginal smear is trans-
ferred to a glass slide and examined under a light microscope
at the same magnification (40–100). Figure 3 describes the
changes in cell types characteristic of the four estrous cycle
stages in the rat.
For both strategies it is important that care is taken to avoid
stimulating the cervix. If the eyedropper or cotton swab
stimulates the cervix with enough pressure during proestrus
or estrus, it can induce pseudopregnancy and, therefore,
disrupt the rat’s estrous cycle for approximately 12 d. Vaginal
cytology should be examined daily, at the same time each
day. Examination of these cells can be used to determine the
cycle length and regularity of multiple cycles for each rat.
Reading the slides. It is not necessary to stain the cells,
because the cells are sufficiently opaque to be visualized
under a microscope with a blue or green filter. Alternatively,
cells obtained via the vaginal smear technique may be fixed
with ethanol (e.g. Surgipath cytology spray; Surgipath Med-
ical Industries, Inc., Richmond, IL) to preserve the sample.
Table 1 provides a protocol for staining the preserved sam-
ples for photographic purposes. The cytology sample can be
viewed under a 40–100 objective with a blue or green filter.
Interpreting the stage of estrous cycle from the cell mor-
phology requires practice and experience with a particular
rat. The precise cellular morphology on a particular day of
the cycle varies with the time of day (especially on proestrus).
Rather than trying to guess what stage of the estrous cycle
a female rat is in, describe the cell types that appear in the
smear. After 5–6 d, it is usually possible to determine what
that rat’s smear looks like on estrus because of the abundance
of cells usually obtained from lavage and their unmistakable
appearance. Collect data for at least two complete cycles
before determining where a female rat is in the cycle. This
same method may be used to monitor the estrous cycle of
mice, but the cells have slightly different characteristics
(68–70).
Question 6: which forms of the hormones should be given to
rodents and by which route of administration?
Just as there are numerous choices in hormone replace-
ment therapy for women lacking ovarian steroid hormone
secretions, there is a wide variety of choices and variables
(form of hormone, time, route, length of administration, etc.)
for hormone replacement in research animals, whose ovaries
have been removed experimentally. In this section, we dis-
cuss some of the hormone replacement procedures that have
been used in rodents, and the rationales for selecting among
them are discussed. Hormones administered to induce sex-
ual receptivity and other physiological responses in female
rats are used as examples. In the many studies on the hor-
monal regulation of sexual behaviors, the many facets of
hormone administration have been extensively studied.
The choice for hormone replacement after gonadectomy
must be guided by consideration of a variety of factors de-
pending on the goals of the study. Is the goal of the study to
1) determine the hormones involved in a particular response
during the estrous cycle or during pregnancy, 2) determine
whether there is a sex difference in a particular response that
is already known to be influenced by the estrous cycle, 3)
determine whether gonadectomized females respond to a
treatment that has a particular effect in gonadectomized
males, or 4) assess whether a particular cellular mechanism
of action of a hormone shows a sex difference in response?
Nomenclature (see also the glossary at the end of this article). There
are two primary classes of ovarian hormones. Estradiol (also
known as 17-estradiol) is the principal circulating hormone
of the class of hormones known as estrogens, and proges-
terone (also known as pregn-4-ene-3,20, dione) is the prin-
cipal circulating hormone of the class known as progestins
(or gestagens). Although 17-estradiol is often referred to as
estrogen, this usage is not technically correct, because 17-
estradiol is a specific hormone, whereas estrogen is a class of
hormones. 17-Estradiol is the most abundant circulating
estrogen in vertebrates, so this is the particular estrogen that
is usually administered in estrogen replacement in research
animals. In males, the testicular hormone is primarily tes-
tosterone, an androgen.
Different estrogens. Although 17-estradiol is typically the
most physiologically active estrogen, this is not the only
estrogen that has been used in endocrine or neuroendocrine
research. For example, in a variety of in vitro systems, estriol
has been compared in effectiveness to 17-estradiol (71). In
some behavioral experiments, estrone has been used rather
than 17-estradiol (72), perhaps in part because it is less
effective than 17-estradiol and less prone to inducing
progesterone-independent feminine sexual behavior.
Routes of administration. 17-Estradiol and progesterone can
be administered by a wide variety of routes of administra-
tion. These include sc, iv, im, ip, and intracranial routes of
administration. In some experiments, to alleviate the incon-
venience of daily injections for long-term treatments, testos-
terone, 17-estradiol, or progesterone, either in crystalline
form (73, 74) or dissolved in peanut oil, has been enclosed in
a small length of silicone tubing. It can also be delivered by
an Alzet mini-pump (75) that delivers a consistent dose of
TABLE 1. Protocol for staining vaginal smears
Step Procedure
1 Dip fixed slides in 95% ethanol
2 Stain in Harris hematoxylin solution for 2.5 min
3 Dip several times in tap water
4 Dip twice in 0.25% hydrochloric acid
5 Dip in distilled water
6 Place in saturated lithium bicarbonate solution for 30 sec
7 Dip in distilled water
8 Place in 95% ethanol for 30 sec
9 Stain in eosin Y solution for 45 min
10 Dip twice in 95% ethanol
11 Coverslip slides
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hormone for days, or by pellets supplied to deliver a par-
ticular dose of steroid hormone daily when implanted sc (76).
Each mode of hormone replacement has its appropriate
place, but different routes and regimens may provide dis-
crepant results. In some cases, these differences in response
to different treatments have been exploited to understand the
hormones-behavior relationships better.
Esterified vs. free hormone. Because the circulating amount of
17-estradiol does not remain elevated for very long after
systemic injection of 17-estradiol, slower-release, esterified
forms of 17-estradiol are often used in physiological re-
search. A variety of esters and other modifications have been
used, such as ethynylestradiol (77), estradiol valerate (78), or
estradiol dipropionate (79). However, the most commonly
used form is estradiol-3-benzoate, which is 17-estradiol
with a benzoic acid esterified in the third carbon position.
This form is hydrolyzed in vivo to the physiologically active
17-estradiol. Progesterone is injected only in an unmodified
form (80). Testosterone is usually administered as testoster-
one or testosterone propionate (81).
In much of the early work in behavioral endocrinology,
estradiol benzoate was the most effective form of estrogen
found to induce sexual receptivity in females when followed
by progesterone (80), so this became standard in the field of
hormonal regulation of feminine sexual behaviors. It is likely
that this form was chosen over free 17-estradiol or estrone
because it is generally effective in lower doses than either of
these free, unesterified estrogens. Interestingly, though,
many years after the pioneering work, others reported that
free 17-estradiol is more effective if given in a pulsatile
fashion (82), for example, with two injections separated by at
least 3–36 h (83).
The most typical mode of administration when attempting
to induce lordosis behavior is one, two, or three daily injec-
tions of estradiol benzoate followed by progesterone. These
treatments reliably induce the expression of feminine sexual
behavior. In some cases, chronic daily injections of estradiol
benzoate have been given without progesterone (84), al-
though progesterone is essential for the facilitation of sexual
receptivity during the estrous cycle (85) and for the full
complement of sexual behaviors in rats (86). Although 17-
estradiol alone may be effective in inducing sexual behavior
and in causing many of the behavioral changes seen during
the estrous stage of the estrous cycle, the injection of daily
17-estradiol or estradiol benzoate does not duplicate the
preovulatory pattern of ovarian steroid hormones seen dur-
ing the estrous cycle for two reasons. The preovulatory 17-
estradiol rises and falls over the course of a day and a half
(See Fig. 2B), and the preovulatory 17-estradiol is also fol-
lowed by a surge in progesterone from the follicle and in-
terstitium (87) (see Fig. 2B). Recently, Asarian and Geary (88)
used a procedure in which a low dose of estradiol benzoate
was injected sc every 4 d in ovariectomized rats. This treat-
ment, which closely mimics the changes in 17-estradiol
concentrations over the estrous cycle, was effective in main-
taining a variety of estrogen-dependent responses including
responsiveness to progesterone facilitation of sexual behav-
ior every 4 d, at rates similar to that seen during the rat’s 4-d
estrous cycle, suggesting that this regimen might be a very
useful strategy for hormone replacement.
Silicone tubing capsules. When the treatment regimen requires
or can accommodate prolonged exposure to the hormones,
17-estradiol, progesterone, and testosterone have often
been administered in the form of crystalline hormone im-
plants in silicone tubing implanted sc (74, 89). Lipophilic
steroid hormones dissolve through the wall of the silicone
tubing and are released at a constant rate that depends on the
surface area (length  diameter) of the capsule and the thick-
ness of the capsule wall. Resulting hormone concentrations
can be titrated by dissolving the hormone in oil vehicle (90)
by diluting it with crystalline cholesterol (91) or by varying
the size of the tubing itself. In addition, concentrations of
circulating hormone remain rather consistent for an ex-
tended period of time (92) compared with injection of 17-
estradiol benzoate or another estrogen (93). To implant and
remove silicone tubing capsules, the animals have to be anes-
thetized. However, they do not need to be handled daily as
would be the case with injections. In some cases, silicone
tubing capsules are inserted and removed at particular in-
tervals, either to approximate hormone concentrations seen
during the estrous cycle (90) or to provide the hormone in a
more-or-less discontinuous pattern (94).
A similar mode of administration that has been used in
mice is chronic implantation of silicone tubing capsules con-
taining 17-estradiol dissolved in oil (95). Often progester-
one is injected weekly before tests for sexual receptivity. On
the background of the chronic 17-estradiol exposure, the
weekly progesterone is quite effective. It must be noted,
however, that although this might be useful in certain types
of studies when prolonged elevation of 17-estradiol con-
centrations is desired, the treatments bear no similarity to the
patterns seen during the estrous cycle, as discussed earlier.
Pharmacokinetics. When replacing hormone by any of the
modes of administration discussed here, pharmacokinetics
must be taken into account. As would be expected, an iv,
unesterified 17-estradiol injection results in an immediate
massive increase in blood 17-estradiol concentrations,
which decline with a time course dependent upon dose of
hormone injected (96). On the other hand, a sc injection of the
esterified estradiol benzoate induces a slower rise and fall of
blood 17-estradiol concentrations, typically lasting for one
(97) or two (88, 98) days. A silicone tubing capsule implanted
sc results in more of a square wave in 17-estradiol concen-
trations with insertion and removal of the capsule (92), al-
though the dynamics can be greatly influenced by whether
crystalline 17-estradiol (91) is used or 17-estradiol dis-
solved in peanut oil vehicle (99, 100). Likewise, the hormone
peak can be influenced by preincubation of the capsules
before insertion (74, 101), the percentage of 17-estradiol
relative to cholesterol in the implants (91), and other factors.
Absence of hormone in blood is not absence of hormone. The
decrease in blood concentrations of 17-estradiol does not
indicate that the 17-estradiol is no longer active. 17-Es-
tradiol is retained by cell nuclear receptors for a considerable
time after the decline in blood concentrations. For example,
18–24 h after an iv injection, 17-estradiol is still bound by
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cell nuclear estrogen receptors (96), functioning as transcrip-
tion factors, long after circulating concentrations of 17-
estradiol have declined. Likewise, 17-estradiol remains
bound to estrogen receptors for at least 2 or 3 d after injection
of a low dose of estradiol benzoate in rats (102) and guinea
pigs (103), and the cellular and behavioral consequences of
the hormone injection may persist for several days (102, 104),
long after circulating concentrations of 17-estradiol have
decreased. In the case of another estrogen, 17-ethynylestra-
diol, residual effects can be observed more than 2 wk after
cessation of treatment (77). Although 17-estradiol concen-
trations circulating in the blood may decline quite rapidly
after removal of a sc silicone tubing implant containing 17-
estradiol (92), the behavioral response persists for at least a
day (94), as does 17-estradiol remaining bound in cells
(105).
Intracranial and iv administration. Sex steroid hormones are
extensively metabolized by the liver. To bypass this metab-
olism or the delay in delivery of the hormone to the neural
site of action, hormones can be infused by cannula directly
into the cerebral ventricles (106). If the neuroanatomical site
of action of the hormones is being investigated, the hormone
can be implanted directly into specific neuroanatomical areas
(107). Similarly, both 17-estradiol (96, 108) and progester-
one (109–111) have been administered iv either to increase
the amount of unmetabolized hormone reaching the brain or
to deliver the hormone to the brain as rapidly as possible. In
some cases, these modes of administration have been used
when the particular compound being administered is costly
(e.g. radioactively labeled estrogen or a difficult-to-isolate
metabolite) or when a route that optimizes efficient delivery
is desirable.
Pulses of hormones and sex differences. The most compelling
evidence that different types of hormone replacement can
produce different results comes from studies of sex differ-
ences in hormone-induced feminine sexual behavior in rats
and guinea pigs. It is well known and accepted that there is
a dramatic sex difference in response of many species to
hormonal induction of feminine sexual behavior; after ovar-
ian hormone treatment, the vast majority of gonadectomized
female rats (112, 113) or guinea pigs (14, 114) express sexual
behaviors, whereas most males do not (for review see Ref.
115). In contrast, if low-dose pulses of free 17-estradiol are
injected in an episodic manner separated by about 12–24 h
and then are followed by progesterone injection, male rats
(116, 117) and guinea pigs (118) express high rates of lordosis,
sometimes as much as females. Although the reason that the
pulses eliminate a quite robust sex difference seen with the
more-typical single injections remains a fascinating mystery,
it exemplifies the importance of considering the many op-
tions of hormonal replacement regimen for a particular
study. The finding that pulse administration eliminates or
attenuates the sex difference in sexual behavior should not
be interpreted as a nuisance or an artifact; rather it tells us
that the male brain interprets episodic 17-estradiol expo-
sure as meaning something different from continuous 17-
estradiol exposure. Because the brain of a female does not
respond in a qualitatively different manner to episodic vs.
continuous 17-estradiol exposure, this represent an intrigu-
ing sex difference in response to different modes of hormone
administration.
Experiments with mice. Mice are not just small rats, and their
neuroendocrine systems are regulated in a number of ways
that are different from rats. In particular, the hormonal reg-
ulation of sexual behaviors is different in mice than in rats,
and even strains of mice can differ markedly from each other.
This is made more difficult for the laboratory scientist by the
relative paucity of information about hormones and brain
function and behavior in mice. Researchers working in rats
or guinea pigs, on the other hand, have a voluminous liter-
ature on the effects of different doses, injection regimens,
routes of administration, and particular hormones to draw
on. A good deal of this work on rats and guinea pigs came
originally from the work of William C. Young’s research
group in the 1930s (80) (see e.g. Ref.119). This work has been
added to and clarified many times over during the past
half-century. This is not the case with mouse reproductive
neuroendocrinology. Many of the critical parametric exper-
iments have yet to be performed in mice. The result is that
mice are used as a model species with which to study mo-
lecular neuroendocrine relationships involved in sexual be-
havior and other aspects of reproductive neuroendocrinol-
ogy; however, unlike the situation in guinea pigs (120) and
rats (85), less is known about the factors necessary for the
induction of feminine sexual behavior during the estrous
cycle. For example, unlike rats and guinea pigs, when female
mice are given typical injections of 17-estradiol followed by
progesterone (106, 121, 122), or when given implants of a
silicone tubing capsule of 17-estradiol followed by pretest
injections of progesterone (95), they do not show full sexual
response until approximately the fourth weekly behavioral
test. Furthermore, chronic estradiol treatment is not well
tolerated by male mice (123, 124).
Complication of dosage in sex difference experiments. A compli-
cation of hormone dose arises when contrasts are made be-
tween males and females. When comparing the response of
the two sexes to a particular hormonal treatment, should an
equivalent amount of hormone be administered per animal
or per body weight? Typically, for a particular age, male rats
will be heavier than females, so providing a constant dose
would be less of a dose to the males per body weight. Un-
fortunately, an informed decision about how to equate a dose
requires a great deal of knowledge about the pharmacoki-
netics for a given hormone in the two sexes of a particular
species and the amount of hormone present in the circulation
after a particular injection (125, 126). These are empirical
questions that will depend very much on the particular ex-
periments and are well beyond the scope of this paper. Ide-
ally, doses of a hormone would be administered to males and
females that result in comparable concentrations of hormone
in the circulation. If hyperphysiological, supersaturating
doses of steroid hormones are administered, the differences
in hormone concentrations may be inconsequential. How-
ever, a dose that produces physiological concentrations in
females does not necessarily deliver an equivalent concen-
tration in males. The pharmacokinetics of hormone and drug
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disposition affects not only the peak of the hormone deliv-
ered but also the time course of hormone present in the blood
system. So, a dose that produces equal concentrations of
hormones in males and females at 30 min will probably not
result in equal concentrations of hormones in blood at 2 h. Of
course, all drugs and hormones are different, so each must
be evaluated independently.
Summary. In summary, this section discussed the most com-
mon modes of administration and regimens used in ovarian
hormone replacement treatment of rats. Each has its advan-
tages and disadvantages, and each can be applied to the
study of sex differences. A great deal of thought must go into
choosing the particular hormones administered, their form,
and the mode and timing of administration, and a good deal
of thought must go into providing equitable treatments in
males and females. Fortunately, much is already known
about the effects of varying particular parameters on phys-
iological responses, so well-informed choices are possible.
Although testicular hormone replacement was not specifi-
cally discussed, all of the same considerations must be made
in administering androgens as in administering estrogens
and progestins.
Question 7: how do you study the stage of the menstrual
cycle and other hormone variation in men and women?
Menstrual cycle. Just as is the case in laboratory animals,
hormonal changes associated with a woman’s reproductive
cycle may contribute to sex differences observed. For exam-
ple, the hormonal changes occurring during the normal men-
strual cycle (i.e. from the follicular phase to the luteal phase;
Fig. 2A) must be taken into account in evaluating many
physiological or brain-based sex differences. The idea that
men are hormonally static is not really true. Men, too, ex-
perience biological rhythms in the production of sex steroids,
including significant diurnal and seasonal changes in tes-
tosterone production (30). A researcher studying sex differ-
ences should be aware of variations in endogenous hor-
mones that may be pertinent to variables under study and be
prepared to monitor them when appropriate. Thus, men-
strual cycle stage in female subjects may need to be deter-
mined. Other major changes in sex steroids that could have
significant implications for sex differences occur at puberty
in both sexes, during pregnancy and the postpartum in
women, and with aging.
During the typical menstrual cycle, serum concentrations
of 17-estradiol range from 30–300 pg/ml (127, 128), and
peak concentrations are achieved directly before ovulation.
It is important to realize that there can be large inter- and
intra-individual variations in the exact timing of menstrual
events and the concentrations of hormones attained at the
various stages. Researchers should not assume that the
length of a woman’s cycle is 28 da In fact, the median length
of the menstrual cycle is 29.5 d, and it is common for women
to have regular cycles as short as 25 or as long as 35 d (127).
Because the length of the luteal phase is relatively fixed at
approximately 13–15 d, variations in cycle length largely
reflect variation in the length of the follicular phase, and the
timing of ovulation will vary accordingly. Concentrations of
progesterone vary from less than 1.0 to around 15 ng/ml
during the normal menstrual cycle, and peak progesterone
concentrations are reached in the mid-luteal phase (127, 128).
Follicular-phase progesterone concentrations are extremely
low, along with concentrations in anovulatory and meno-
pausal women. The late luteal phase is associated with a
reduction in serum concentrations of 17-estradiol, proges-
terone, or 17-estradiol and progesterone. FSH concentra-
tions range from less than 1.0 to 12 mIU/ml, whereas LH
concentrations range from less than 2.0 to around 50 mIU/ml
and peak at the time of ovulation (see Fig. 2A). Menstruation
onset can be determined by simply asking women them-
selves or by analyzing hormone concentrations and com-
paring them with a chart similar to Fig. 2A.
Analyzing vaginal secretions (for day of maximum cervi-
cal mucus), analyzing urine samples (for daily estrone con-
jugates revealing ovarian follicular dynamics), taking basal
body temperature, and using ovulation kits are all methods
that can provide information regarding the approximate tim-
ing of ovulation (129, 130). Not all methods may be equally
useful in a given study. For example, the rise in body tem-
perature is small (between 0.2 and 0.5 C), occurs only after
ovulation has transpired, and does not occur reliably in all
women, even if cycles are ovulatory. Knowing the time of
ovulation, however, can aid in the determination of the men-
strual cycle stage of a female subject. To permit the proper
adjustments to be made for menstrual cycle length, women
should be asked to chart their cycle if there is doubt about its
typical length. Monitoring two or more cycles may be needed
to derive a reliable estimate (131). Although more elaborate
methods are also available, this could be as simple as re-
cording the date of menstrual onset over several cycles.
Puberty. The stages of puberty are conventionally defined in
both sexes by the degree of development of secondary sex
characteristics and rated on the Tanner scale (132). A com-
plete description of the hormonal changes and stages of
puberty in humans is beyond the scope of this article. Pu-
berty is a time when females undergo major hormonal
changes associated with the menstrual cycle (133). There is
also a dramatic rise in androgen production in males.
Menopause. Menopause results from a sequence of events that
leads to a modification in the programming along the hy-
pothalamic-pituitary-gonadal (HPG) axis. After the meno-
pause, production of 17-estradiol and estrone by the ovaries
declines considerably. A relationship between declining
ovarian hormone concentrations and the symptoms of meno-
pause has been suggested. The reciprocity between gonadal
hormones and the serotonergic system presents some prom-
ising clues into the mechanism that initiates the onset of
menopausally related neuroregulatory changes (134, 135).
Effects of hormones in humans. As mentioned earlier, to observe
the effect that gonadal hormones have on human subjects in
a study, the gonads cannot ethically be removed as they can
in animals. Hormone concentrations, therefore, must be ma-
nipulated (i.e. added or reduced). This can be accomplished
by capitalizing upon endogenous biological rhythms in ste-
roid production or, ideally, by adding or removing hormones
experimentally. For instance, women taking exogenous go-
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nadal steroids for contraceptive purposes (e.g. oral contra-
ceptives and GnRH analogs) or for therapeutic purposes (e.g.
HRT) to palliate menopausal symptoms such as hot flushes
and vaginal dryness or mood symptoms or GnRH analogs to
treat premenstrual dysphoric disorder can be studied. Op-
portunities to study men are less frequent but include med-
ical interventions such as androgen blockade in prostate
cancer or testosterone replacement to prevent bone loss in
men with HIV.
As one example, oral contraceptives suppress ovulation
while sustaining menstruation due to regular steroid with-
drawal. Presently, all low-dose oral contraceptives contain
ethinyl estradiol in 20-, 30-, or 35-g doses (136). These for-
mulations are low in estrogen compared with the oral con-
traceptives that were on the market 25 yr ago. Presently,
contraceptives containing 75–100 g of mestranol or ethinyl
estradiol are no longer available. Oral contraceptives con-
taining 50 g of ethinyl estradiol are available but mostly
reserved for therapeutic situations where a higher dose of
estrogen is required. The estrogen formulation used most
frequently for HRT is Premarin, which is composed of con-
jugated equine estrogens that are a mixture of estrone sulfate
(50%), equilin sulfate (23%), 17-dihydroequilin sulfate
(13%), and a variety of other conjugated estrogens (136).
The intestine inadequately absorbs progesterone. Two
methods have been employed to make it orally active. One
is to micronize the preparation. Progesterone has also been
altered at C-17 and C-6 to make the potent oral progestins
megestrol acetate and medroxyprogesterone acetate (136).
GnRH analogs can be administered sc or nasally to induce
anovulation in women. GnRH agonists suppress ovulation
because they down-regulate GnRH receptors in the hypo-
thalamus, leading to decreased FSH and LH release from the
pituitary, resulting in decreased estrogen and progesterone
concentrations (137). In comparison with placebo, GnRH
analogs are more effective at reducing cyclical mood changes
related to the menstrual cycle (138–140). Long-term use of
GnRH agonists is restricted by the incidence of side effects
that mimic menopause and elevated risk for hypoestro-
genism and osteoporosis. Evidence suggests that add-back
therapy may help avoid some of these side effects (141).
Intranasal buserelin at 400–900 g daily or im leuprolide at
3.75–7.5 mg per month are the most suitable GnRH treat-
ments for use clinically. Add-back therapy should be com-
posed of conjugated estrogen at 0.625 mg daily (Monday to
Saturday) and 10 mg of medroxyprogesterone acetate daily
for 10 d during every fourth menstrual cycle (137).
Question 8: what are the effects of sex differences in
pharmacokinetics and pharmacodynamics on the effects
drug treatment?
Sex-related differences in drug effects. When measuring the re-
sponse of males and females to drugs, it is important to
remember that there may be pronounced sex differences.
These arise from differences in pharmacodynamics (phar-
macological effect on the body) and pharmacokinetics (ab-
sorption, distribution, metabolism, and excretion, or ADME)
(for a review see Ref. 142). Pharmacodynamic differences
have been reported for a number of drug classes, including
analgesics, antidepressants, antipsychotics, and muscle re-
laxants. The underlying mechanisms, such as hormone-drug
signaling interactions, are poorly understood and therefore
not readily generalized. A careful survey of the literature is
needed for each drug under study; moreover, one needs to
recognize that sex difference may be species dependent. On
the other hand, factors contributing to pharmacokinetic sex
differences have been extensively documented for many spe-
cies and provide a framework for anticipating differences in
drug response between males and females. Sexually dimor-
phic metabolism of drugs and xenobiotics in the liver has
been extensively documented (142). Physiological differ-
ences, summarized in Table 2, can cause higher plasma con-
centrations and longer half-lives of certain medications in
women compared with men, including antidepressants. The
tendency of women to have elevated plasma concentrations
and longer half-lives of drugs may result in a higher inci-
dence of side effects in women compared with men (143);
however, plasma half-lives may also be shorter in females
compared with males (142). The pharmacokinetics of certain
drugs may also be altered by age. For example, younger
women with depression are more responsive to serotonergic
antidepressants (144). Similarly, changes do occur in males,
for example with the circadian rhythm and with age, but
potentially with different rates and amplitudes than in
females.
Menstrual cycle. Hormonal fluctuations can have a strong
effect on drug response in females. The endogenous hor-
monal changes that occur across the menstrual cycle have
been associated with physiological changes that may affect
pharmacokinetics in women. For example, compared with
the follicular phase, the late luteal or premenstrual phase of
the menstrual cycle is correlated with reduced gastric acid
secretion as well as slower gastric emptying and short in-
testinal transit times (145). Other potential effects consist of
increases in total body water, hepatic metabolism, creatinine
clearance, and sodium retention (145).
A premenstrual reduction in drug concentrations is the
main effect of these alterations (145). For instance, reductions
in steady-state concentrations of desipramine and trazodone
by as much as 53% during the late luteal phase have been
reported (146). This may lead to the observance of sex dif-
ferences in drug pharmacokinetics during the luteal phase
but not the follicular phase, as has been reported for the
TABLE 2. Physiological differences in women that may affect
drug pharmacokinetics
Physiological difference
Higher percentage of body fat
Higher cerebral blood flow
Slower gastric emptying time
Decreased gastric acid secretion
Lower body weight
Less blood volume
Lower plasma protein binding
Lower hepatic biotransformation
Slower renal clearance
[Adapted with permission from: S. G. Kornstein and C. K. Kirk-
wood: Handbook of Female Psychopharmacology (edited by M.
Steiner and G. Koren), Martin Dunitz, London, 2003, p 1 (143).]
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kinetics of lithium. There is also evidence that monoamine
oxidase activity is reduced by estrogens and elevated by
progesterone, suggesting that hormonal fluctuations (endog-
enous as well as exogenous) may affect mood in an unpre-
dictable manner (147, 148).
Numerous studies have addressed the question how hor-
mones affect drug metabolism and more specifically the ox-
idative cytochrome P450 enzymes, such as CYP3A4 (the
main drug metabolizing CYP showing a tendency of greater
activity in females), CYP2C9/19, CYP2D6, and CYP2E1. Al-
though some studies have observed consistent changes as a
function of hormonal effects, this depends on the CYP
isozyme and the tissue analyzed. Overall, the changes do not
appear to be dramatic in humans. In contrast, there are male-
specific CYP isozymes in rats (CYP3A2 and CYP2C11) that
can be induced in female livers upon administration of an-
drogens (142). Even the induction of certain CYP isozymes
by xenobiotics can show strong sex differences. Oral contra-
ceptives may increase the metabolism of drugs that undergo
conjugation or glucuronidation and, hence, may affect the
clearance of drugs that are metabolized by oxidation in fe-
male patients (143). For example, decreased clearance and a
63% increase in the absolute bioavailability of imipramine
was reported to be associated with concomitant oral contra-
ceptive use (149). Taken together, pharmacokinetics and
pharmacodynamics display clear differences between males
and females. The magnitude of such differences varies with
the drug under study, the species, tissue, and experimental
conditions.
Pregnancy. During pregnancy, plasma concentrations of the
acute-phase protein 1-acid glycoprotein vary dramatically
(150). Because 1-acid glycoprotein represents a major drug-
binding component in plasma, particularly under stimulated
conditions, this affects the disposition of numerous drugs
by enhancing plasma protein binding and affecting drug
disposition.
There are also physiological changes of pregnancy that
affect drug metabolism, including slowed gastric emptying,
reduced gastrointestinal motility, increased volume of dis-
tribution, reduced protein binding capacity, and increased
hepatic metabolism, which can substantially affect pharma-
cokinetic parameters that may lead to observed sex differ-
ences (151). For instance, in a study of the dose requirements
for tricyclic antidepressants to ameliorate depressive symp-
toms during pregnancy, rising doses were required in the
second half of pregnancy, with rapid dose escalation in the
third trimester. The ultimate dose attained was about 1.6
times the prepregnancy dose (152).
Menopause. Menopausal status may also affect pharmacoki-
netic parameters, although it is sometimes difficult to sep-
arate the effects of menopausal status from the effects of age.
Generally, one would expect reduced clearance, extended
half-lives, and elevated plasma concentrations of medica-
tions (143). Exogenous hormone use, including HRT in post-
menopausal women, oral contraceptives, and GnRH analogs
may have confounding effects on the pharmacokinetics of
other drugs that are administered. Conjugated HRT de-
creases (liquids) and increases (solids) gastric emptying
times, reduces gastric acid secretion, and has variable effects
on protein binding (145).
Question 9: when doing research on sex differences in
humans, is it really necessary to measure hormone
concentrations?
It depends on the research question being asked. If the
organizational effects of sex steroids are being studied, mea-
suring hormones is usually not feasible. This is because the
behavior of interest is normally studied in childhood or
adulthood, whereas the active hormones were present early
in development, often prenatally. There is no practical way
to measure hormone concentrations in the fetus. A few stud-
ies have tried measuring testosterone or other hormones in
human amniotic fluid (e.g. (153), but because the amniocen-
tesis procedure is performed at a fixed time in development,
this method can at best provide a glimpse of individual
differences in hormone concentrations, based on a single
specimen, at one fixed time point. Whether this time point is
important for any aspect of neuronal differentiation, and
what behavioral systems might go through a critical period
at that time, are unknown. There has been speculation (154,
155) that some aspects of sexual differentiation may occur in
the first 6 months of postnatal life. If the speculations turn out
to be true, it will open the door to researchers using direct
measures of infants’ hormones to study organizational ef-
fects. It may then be possible to link concentrations of specific
hormones directly to patterns of behavioral development.
In situations where organizational effects are studied us-
ing clinical conditions, such as CAH, which was discussed
above, it is still a technical problem to access fetal hormones.
In addition, many of these conditions are not diagnosed until
after birth. This means the hormonal abnormality is not rec-
ognized during the time when the central nervous system
effects are presumably occurring. But in CAH, direct mea-
sures of hormones are a normal part of the postnatal diag-
nostic work-up. Serum assays of 17-hydroxyprogesterone
and androgens, such as androstenedione or testosterone,
may be useful during the period from birth to 2 wk after
birth, or the point when treatment is usually initiated. On-
going monitoring of hormones by a pediatric endocrinologist
in children with CAH is used to help establish whether the
patient’s hormones are under satisfactory drug control. The
clinical records can be useful to researchers for establishing
that any androgen excess is limited to the period before
treatment is initiated.
Direct vs. indirect manipulations of hormones. In most research
situations where sex differences are studied, direct measures
of hormone concentrations are desirable and often essential.
The fact that the current hormone environment can modify
the size of behavioral sex differences means that it is almost
always good practice to measure the concentrations of rel-
evant hormones. Even in situations where a dynamic effect
is not suspected, it is worthwhile to measure hormones to
demonstrate that such an effect is not present. But more
often, researchers might find themselves in situations where
a sex difference may need to be assessed at two or more
concentrations of a given hormone. For instance, if there is
a menstrual cycle effect on a particular behavioral or physical
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variable, one might wish to assess the variable at high and
low concentrations of 17-estradiol or progesterone. In this
situation, confirmation of the 17-estradiol or progesterone
concentrations would be required to demonstrate that the
hormones varied as expected. In addition to changes in ovar-
ian hormones over the menstrual cycle, a variety of other
endogenous variation in steroid hormone concentrations can
be used to manipulate hormones. For example, there are
diurnal changes in testosterone and cortisol release (32, 156).
However, it must be kept in mind that these manipulations
are indirect methods of studying the effects of a particular
hormone. Because there is variation across individuals in the
timing and concentrations of hormones attained, actual mea-
surement of hormone concentrations is usually essential to
verify that the expected changes in hormones are present and
therefore that the manipulation is valid. For instance, on
average, men’s free testosterone concentrations decline by
50% between ages 30 and 80 (31). However, there are some
80-yr-olds who have higher testosterone than some 35-yr-
olds. Therefore, the only way to conclusively demonstrate
that testosterone is lower in the older group is to measure it
directly.
It is particularly important to include direct measurement
of ovarian hormones when doing menstrual cycle studies.
Historically, this has not always been done. There are a few
situations where the timing of the cycle itself is of interest,
such as in studies of premenstrual syndrome or in studies
where disruptions in the length or regularity of the cycle are
significant endpoints. More typically, the goal of the work is
to draw inferences about the actions of reproductive hor-
mones. In this situation, tracking the phases of the cycle is
insufficient. Phases of the menstrual cycle in women are
defined either by their timing (e.g. the mid-luteal phase oc-
curs about 1 wk before the onset of menstruation) or by
associated events (e.g. the presence of menses), not by the
exact concentrations of hormones achieved. Therefore, if the
purpose of a study is to make inferences about a particular
hormone, there is no substitute for directly measuring the
hormone itself. This is especially true because there are large
individual differences in the precise concentrations of hor-
mones attained at each phase of the cycle and in the timing
of menstrual cycle events across individual women and
across multiple cycles within an individual woman. Con-
versely, it is not possible to tell whether a woman is in the
middle of the luteal phase, based strictly on the concentra-
tions of 17-estradiol and progesterone that are present.
What constitutes a mid-luteal value in one woman may only
be an early luteal phase value in another. Large parts of the
cycle cannot be confirmed through hormonal measurements
alone because of the individual differences in hormone con-
centrations attained and can only be verified retrospectively
based on the onset of the next menstrual period or by fol-
lowing changes in hormones over a number of menstrual
cycles.
Another method for studying the effects of hormones on
brain function is to manipulate hormone concentrations di-
rectly. In humans, options for doing this are limited by ethical
considerations. As noted earlier, effects of HRT in older
women have been studied as a way of experimentally ma-
nipulating estrogen concentrations. Less attention has been
paid to the progestin component of HRT. The effects of
testosterone replacement in older men have also been stud-
ied in a few investigations (e.g. Ref. 157). Randomized con-
trolled trials are the best method for studying the effects of
a hormonal manipulation. However, because randomized
controlled trials are typically short-term, they do not mimic
the natural conditions under which many people use hor-
mones and cannot detect cumulative long-term effects of the
hormone treatments. Therefore, studies of long-term users
and nonusers also have an important role to play. In this type
of study, however, matching on a large range of relevant
health and demographic variables is of the utmost impor-
tance. In studies where a hormone is directly administered
or suppressed, hormone assays still have an important role
to play. For instance, there may be questions of compliance
that the assays can address, or questions related to how
individual differences in metabolism relate to outcomes. Re-
searchers must ensure the target hormones of interest are
accurately reflected in their assay. Not all synthetic hor-
mones can be detected using standard assay procedures (e.g.
ethinyl estradiol, the estrogen used in most oral contracep-
tives, has low cross-reactivity with the antisera used in con-
ventional RIA kits, and, therefore, special assays must be
performed to detect it).
Serum vs. saliva assays. Finally, is serum or saliva the better
medium for quantifying hormone concentrations? Measur-
ing hormones in serum is still the most widely used method
for measuring hormone concentrations in both research and
clinical settings. Direct assays are available for a wide range
of peptide and steroid hormones, including the full range of
reproductive hormones relevant to sex difference studies.
The assays are well validated, widely available, and can be
performed by most commercial laboratories using isotopic or
nonisotopic techniques.
Saliva-based assays are a recent innovation and are widely
used in Europe, at least for some hormones (e.g. cortisol).
Saliva-based assays have been slower to catch on in North
America but offer some important theoretical advantages. In
particular, most assays of serum hormone concentrations
measure the total hormone in blood, whereas saliva-based
assays measure the unbound, or more accurately the bio-
available fraction, of a steroid hormone (158). Saliva-based
assays, therefore, provide a useful index of precisely that
fraction of the hormone that exerts biological effects (see
Table 3 and Figs. 5 and 6). This derives from the fact that large
peptides cannot diffuse from blood into the saliva, so steroids
bound to binding globulins will not be found in saliva. On
the downside, it also means that a smaller spectrum of hor-
mones is represented in saliva compared with serum (e.g. LH
and FSH are not found in saliva to any significant extent). The
ease and cost-effectiveness of saliva collection, long shelf-life
at ambient temperatures, and noninvasiveness of the proce-
dures offer significant advantages in some research settings.
For instance, endocrine studies involving children, repeated
specimen collection over minutes, days, or weeks, and field
studies that involve specimen collection outside the labora-
tory are more feasible. Technical obstacles associated with
the detection of lower hormone concentrations have been the
challenge for developers of saliva-based assays and explain
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the slow adoption of this promising technology. Because
only the free or bioavailable fraction is contained in saliva,
the concentrations are often near or below the lower detec-
tion threshold of standard immunoassays. Nevertheless,
techniques are under development and rapidly gaining ac-
ceptance. Although still not as widely available as serum
assays, mature assays are available in saliva for cortisol (Fig.
5), progesterone, and testosterone (in men; see also Fig. 6)
(159, 160). 17-Estradiol remains technically difficult to mea-
sure in saliva, and working assays are generally available
only through a few research labs at present. The measure-
ment of testosterone in women is still controversial in both
serum and saliva. A recent review showed that in serum,
only two of 10 commercially available immunoassays gave
an accurate measurement of testosterone in women, judging
by concurrent gas chromatography-mass spectrometry on
the same specimens (161). Saliva kits were not assessed.
Researchers interested in using saliva-based assays must
carefully research their assay and collection procedures. The
ease of collection disguises the many pitfalls awaiting the
unwary investigator. For instance, use of cotton as a collec-
tion device is fine for cortisol but produces inaccurate read-
ings for many other steroids (162). Steroids in saliva are less
vulnerable to enzymatic breakdown than in serum but are
still subject to bacterial degradation of the specimens.
Amending specimens with sodium azide to reduce bacterial
activity is often recommended but can interfere with some
types of immunoassays. Care must also be taken in the choice
of a saliva stimulant, use of plastic vs. glass for storage, and
when to prepare the mouth for specimen collection. A useful
review of some of the critical variables can be found in Ref.
163 or 164. For a general introduction to saliva hormone
monitoring, see Ref. 165 or 166.
Question 10: how does stress impact the study of
sex differences?
Although many describe the HPG axis as a simple closed
biological system, there are other factors that can influence
hormone secretion patterns and, thus, sex differences. Im-
mediately relevant to the study of sex differences is the effect
of stress and stress hormones (e.g. catecholamines and glu-
cocorticoids) on both male and female physiology and be-
havior. Animal and human studies indicate that gonadal
steroid secretion is markedly altered by stress and glucocor-
ticoids in a sex- and hormone-dependent fashion. In addi-
tion, sex steroids themselves can differentially affect stress
responsiveness and can thus result in differential respon-
TABLE 3. Hormone levels: comparison of seruma and saliva concentrations
Hormone No. of specimens R value Citation
17-OH progesterone (total serum vs. saliva) 13 0.98 (196)
Estriol (unconjugated) 24 0.97 (197)
Cortisol (free) 93 0.97 (193)
Human chorionic gonadotropin 24 0.56 (198)
Progesterone (total serum vs. saliva) 96 0.88 (199)
Estradiol (total serum vs. saliva) 14 0.82 (200)
Cortisol (total serum vs. saliva) 13 0.93 Diagnostic Systems Laboratories, Inc. (Webster, TX)
[Adapted with permission from L. Hofman: J Nutr 131:16215, 2001 (165). © American Society for Nutritional Sciences.]
FIG. 5. Cortisol in saliva closely reflects the bioavailable fraction of
the hormone in serum. The bioavailable component of a steroid hor-
mone is often the component of interest in research studies, and saliva
has desirable qualities as a medium for quantifying steroid hormones.
Shown here are correlations between saliva and serum measures
cortisol in men and women. Saliva assay techniques are less well
developed than for serum. Therefore, researchers who elect to use
saliva must take care to choose an assay technique that is well val-
idated to ensure accurate results. [Adapted with permission from R.
Vining et al.: Ann Clin Biochem 20:329, 1983 (193). © Association of
Clinical Biochemists.]
FIG. 6. Correlation of unbound serum and salivary testosterone con-
centrations. [Adapted with permission from J. Vittek: Life Sci 37:711,
1985 (194). © Elsevier, Inc.]
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siveness to incidental stress in males vs. females or gonadally
manipulated animals on behavioral or pharmacological mea-
sures (Fig. 7). Thus, it is important to consider the potential
mitigating influence of stress and stress hormones when
planning experiments.
Laboratory animals. The negative impact of stress on the ro-
dent HPG axis has been documented in numerous studies
(see Refs. 167–170 for review). As depicted in Fig. 7, acute
stress can inhibit GnRH and LH secretion. This can happen
within minutes, likely through direct actions of CRH on
GnRH neurons (171). Chronic stress disrupts the HPG axis
at multiple levels; chronic stress reduces release of GnRH at
the median eminence, decreases pituitary sensitivity to
GnRH, and directly interferes with LH stimulation of sex-
hormone-producing cells (see Ref. 172). Stress inhibition of
the HPG system occurs in both female and male rats (see
(173). Physical stressors such as infection also appear to in-
volve glucocorticoids as part of the mechanism involved in
their suppression of the HPG axis (174).
It is also important to note that in some systems, stress may
have opposite effects in males and female (175, 176). Thus,
incidental, noncontrolled stress exposure has the potential to
produce effects that are associated with sex differences in the
stress response, rather than sex differences in the particular
parameter being explored.
Activation of the hypothalamic-pituitary-adrenal (HPA)
axis produces both between-sex and within-sex differences
in activation that can play a role in behavior and physiology.
For example, in rats, both basal and stress-induced cortico-
sterone secretion is more pronounced in females than males
(177, 178). Whereas basal hypersecretion may be in part ac-
counted for by elevated corticosteroid-binding globulin in
females (178), corticosterone responses to stress remain ex-
aggerated, reflecting a greater net impact on glucocorticoid
secretion. In addition, HPA secretion profiles vary across the
estrous cycle in the rat; proestrous or estrous females show
elevated basal and stress-induced corticosterone levels rel-
ative to diestrous animals (177, 178), consistent with a hy-
pothesized HPA-facilitatory action of estrogens. Thus, the
influence of cyclically secreted or administered gonadal ste-
roids may cause a disproportionate impact on female rats
exposed to incidental stress exposure.
It is important to consider the manipulation of the male
when conducting sex differences studies. Surgery is known
to produce lasting effects on the HPA axis (179, 180), and thus
it is critical that sex differences studies involving gonadec-
tomy employ appropriate operated control groups. In addi-
tion, vaginal smears likely produce some degree of a stress
response in female rats; although there is no equivalent in the
male, it is important that males have parallel handling to
account for this potential difference in stress history.
Finally, the impact of the glucocorticoids on the HPG axis
may vary with the time of day. The HPA axis shows a marked
circadian rhythm, with corticosteroids peaking at the onset
of the active phase of an animal’s or human’s light-dark cycle
(see Ref. 156). The change in concentrations of corticosterone
from nadir to peak can exceed 40-fold, with binding of cog-
nate receptors shifting from minimal to extensive (181). Cor-
respondingly, the impact of glucocorticoids on behavioral
and physiological sex differences may depend on the time of
testing within the animal’s light-dark cycle. Overall, glu-
cocorticoid fluxes associated with stress or the circadian cycle
can clearly inhibit the HPG axis and need to be taken into
account in sex difference studies in rodents.
Humans. In humans, studies suggest that stress is also in-
hibitory to the reproductive axis. However, because we can-
not intentionally subject women to long-term stress, the
evidence is more circumstantial. The classic example of
stress-induced inhibition of the reproductive axis is hypo-
thalamic amenorrhea, also known as stress-induced amen-
orrhea. In this disorder, slowing of LH pulses in the presence
of low 17-estradiol and progesterone suggest a central me-
diation of the effect of stress acting directly on the LH pulse
generator (182). Most disorders of reproductive functioning
in humans (e.g. hypothalamic amenorrhea, exercise-induced
amenorrhea, and anorexia nervosa) are accompanied by ac-
tivation of the HPA axis (183–185). However, the link is not
definitive, and data to date do not suggest marked repro-
ductive abnormalities in major depression, despite docu-
mented activation of the HPA axis (186, 187). Although most
of the nonhuman primate data have concentrated on CRH as
the primary mediator of this inhibition, there are some data
suggesting that glucocorticoids may also be an important
mediator. Cushing’s syndrome, a disorder of extremely high
cortisol production caused by either a pituitary or adrenal
adenoma, is accompanied by inhibition of the reproductive
FIG. 7. Interactions between the HPA and the hypothalamic-pitu-
itary-ovarian axes (solid lines and broken lines represent stimulatory
and inhibitory actions, respectively; the question mark reflects un-
certainty regarding the locus of central estrogen action on the HPA
axis). [Reproduced with permission from E. Young and A. Korszun:
Psychiatr Clin North Am 21:309, 1998 (195). © Elsevier, Inc.]
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axis and infertility. Diminished LH response to GnRH after
long-term prednisolone treatment has been found in women
(188). Stress also results in inhibition of testosterone secretion
in men, secondary to inhibition of the central HPG axis (189).
As in rodent models, time of day of assessment of any end
point is an important consideration. The peak of the HPA
axis in humans occurs around awakening with the nadir
around bedtime or shortly after falling asleep. In humans,
there is strong circadian entrainment in the reproductive axis
during puberty, when LH secretion occurs predominantly at
night. In sexually mature humans, there is still some circa-
dian rhythm in reproductive hormones that can be altered by
disease states so the circadian rhythm should be considered
in reproductive hormone assessment (190).
Summary. In light of the potential confounding effects of
stress on measures of sex differences in brain and behavior,
it is highly recommended that studies of sex differences be
designed with the possible impact of stress in mind. Specif-
ically, 1) efforts should be taken to limit extraneous sensory
stimuli in animal holding rooms or experimental environ-
ments; 2) if procedures must involve handling or restraint
(e.g. injections), subjects should be well habituated to the
procedure before the actual testing session to obviate pos-
sible effects of an acute stress response; and 3) time of day
needs to be considered in all experimental designs. If possible,
the time of testing should be held constant across conditions, to
eliminate the possibility that diurnal glucocorticoid changes
can modulate gonadal steroid-regulated processes.
Closing comments
Studies that are carefully designed to test a clear hypoth-
esis regarding sex differences and the effects of gonadal
steroids are crucial to achieving two distinct, though related,
aims. One is to determine whether a sex or gender difference
has significant clinical relevance in humans and should,
therefore, be considered in developing and using preventive,
diagnostic, or therapeutic interventions. The other is to fur-
ther our understanding of human and animal biology, to
answer the question, “What does this difference tell us about
the underlying biology of this system?”
The importance of sex differences has long been recog-
nized by neuroscientists, beginning with early descriptions
of sexual dimorphisms in behavior and neuroanatomy (7, 14,
191, 192). Significant advances in the technology available for
studying the nervous system are now coupled with a more
complete understanding of the interconnectedness of the
nervous and endocrine systems. A thorough understanding
of the capabilities and challenges of research methods in this
area is a necessary prerequisite to designing studies that take
advantage of current knowledge and thinking in this area.
For those who work at, or consider entering, the intersec-
tion of endocrinology and neuroscience, the choices of ex-
perimental models, designs, and methodologies may seem
daunting. It is hoped that this paper provides useful guid-
ance in addressing these choices, and the authors welcome
readers’ comments and additions to this work.
Glossary
Androgens. A class of sex steroid hormones associated with the devel-
opment and maintenance of the secondary male sex characteristics,
sperm induction, and sexual differentiation.
Aromatase. An enzyme that converts testosterone to 17-estradiol.
Assay. The determination of the amount of a particular constituent of a
mixture or of the biological or pharmacological potency of a drug.
Basal body temperature. The temperature taken at its lowest point in the
day, usually in the morning before getting out of bed.
Classic endocrine experiment. Endocrine gland removal followed by hor-
mone replacement therapy.
Congenital adrenal hyperplasia (CAH). A genetic disorder present at birth
characterized by a deficiency of the hormones aldosterone and cortisol
and an overproduction of androgens.
Conjugated equine estrogens. Thought to be the active ingredients in Pre-
marin; conjugated refers to the fact that the estrogens are chemically
bonded to a sulfate group, and equine refers to the fact that the hormones
are isolated from urine collected from pregnant horses.
Corpus luteum. A yellow glandular mass in the ovary formed by an
ovarian follicle that has matured and discharged its ovum. The corpus
luteum secretes progesterone.
Defeminization. Any change that renders an animal less like typical
females.
Demasculinization. Any change that renders an animal less like typical
males.
Endogenous. Developing or originating within the organism or arising
from causes within the organism.
Estradiol. 17-Estradiol is a sex steroid hormone synthesized mainly in
the ovary, but also in the placenta, testis, and adrenal cortex.
Estriol. A metabolite of 17-estradiol and usually the predominant es-
trogenic metabolite in urine. During pregnancy, large amounts of estriol
are produced by the placenta.
Estrogens. A class of sex steroid hormones associated with expression of
secondary female sex characteristics, predominantly synthesized by the
ovary.
Estrone. A metabolite of 17-estradiol but possessing less biological
activity. It is found in the urine of pregnant women and mares. It is also
the dominant hormone found in postmenopausal women.
Estrous. Adjective that refers to the female reproductive cycle or the day
of behavioral estrus when used to modify a noun such as estrous cycle
or estrous female.
Estrus. Noun that refers to that portion or phase of the reproductive cycle
of female animals characterized by ovulation and willingness to permit
coitus.
Fadrozole. A selective aromatase inhibitor.
Feminine. Describes traits that are typical of females.
Feminization. A change that makes an animal more like typical females
(not the same as demasculinization).
Flutamide. An androgen receptor antagonist.
Follicular phase. The follicular phase, also referred to as the proliferative
phase, is the preovulatory phase of a woman’s reproductive cycle during
which the follicle grows and high serum estrogen concentrations cause
the uterine lining to grow.
Glucocorticoids. A class of adrenal steroid hormones that affect carbo-
hydrate metabolism (gluconeogenesis, liver glycogen deposition, and
elevation of blood sugar), inhibit corticotropin secretion, and possess
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pronounced antiinflammatory activity. Glucocorticoids can inhibit go-
nadal secretions.
Gonadotropin-releasing hormone (GnRH). A peptide hormone that is pro-
duced and released by the hypothalamus and regulates the production
and release of gonadotropins from the pituitary gland.
Hormone replacement therapy (HRT). Also referred to as hormone treat-
ment, or HT. Administration of hormones, commonly used to refer to
treatment with estrogens and often progestins after menopause.
Lordosis. The position that estrous females of many species exhibit when
a male mounts. The position is characterized by dorsiflexion of the
lumbar curvature of the spine.
Luteal phase. The postovulatory phase of the female reproductive cycle,
also referred to as the secretory phase.
Masculine. Describes traits that are typical of males.
Masculinization. A change that makes an animal more like typical males
(not the same as defeminization).
Müllerian-inhibiting hormone (substance). A glycoprotein secreted by the
embryonic testis that causes involution of the Müllerian duct systems.
Progesterone. A progestin synthesized mainly in the ovary.
RU486. A progestin and glucocorticoid receptor antagonist.
Sexual dimorphism. The differences between female and male individuals
of a species.
SRY. A gene found on the Y chromosome that determines the formation
of testes.
Tanner scale. A standardized method for describing the stage of pubertal
development in humans that uses parameters of physical development
that requires assessment of secondary sex characteristics.
Testosterone. Sex steroid hormone, of the class of androgens, secreted by
gonads and adrenals.
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